RxDoctor Payments Data

Mark Higgins, MD

Internal Medicine · San Francisco, CANPI 1134193469

Payments from drug & device makers

$75,325in general payments, 2019–2025

Across 1,499 payments — averaging $50.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$42K
  • Viiv Healthcare Company$13K
  • AbbVie$3K
  • EMD Serono, Inc.$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$7,31010%
  • Speaking & faculty fees$33,44344%
  • Travel & lodging$3,4515%
  • Food & beverage$30,91441%
  • Education$2070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead197$41,522
Viiv Healthcare Company261$13,123
AbbVie(2 entities)163$2,761
EMD Serono, Inc.120$2,213
Novo Nordisk89$1,442
AstraZeneca65$1,410
Merck63$1,357
Lilly USA, LLC51$1,021
Johnson & Johnson(2 entities)60$974
Pfizer46$900
Theratechnologies Inc.28$759
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$573
Napo Pharmaceuticals Inc25$556
Bausch Health US, LLC30$547
Collegium Pharmaceutical, Inc.24$461
Amarin Pharma, Inc.25$451
Takeda Pharmaceuticals U.S.A., Inc.18$392
Antares Pharma, Inc.17$387
Otsuka America Pharmaceutical, Inc.15$360
Boehringer Ingelheim21$318
GSK11$261
Amgen11$259
Axsome Therapeutics, Inc.3$256
Indivior Inc.7$247
Teva Pharmaceuticals USA, Inc.9$234
Janssen Products, LP2$199
Eisai Inc.9$159
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$149
Nestle Healthcare Nutrition Inc.6$134
E.r. Squibb & Sons, L.L.C.6$131
Kowa Pharmaceuticals America, Inc.6$123
Verity Pharmaceuticals Inc.5$108
Janssen Scientific Affairs, LLC5$107
Almatica Pharma LLC4$106
Boston Scientific1$102
Biohaven Pharmaceuticals, Inc.4$94
Aimmune Therapeutics, Inc.2$83
Idorsia Pharmaceuticals US Inc4$83
Sanofi-aventis U.S. LLC4$81
Novartis4$80
Oxford Immunotec USA Inc3$80
Ironwood Pharmaceuticals, Inc4$72
Biohaven Pharmaceutical Holding Company Ltd.3$71
Bayer3$63
Exact Sciences2$61
Adlon Therapeutics L.p.3$57
Mylan Specialty L.p.3$57
Vanda Pharmaceuticals Inc.2$44
Lundbeck LLC1$32
Biodelivery Sciences International, Inc.2$29
Azurity Pharmaceuticals, Inc.1$26
Esperion Therapeutics, Inc.1$24
Halozyme Inc1$23
Vivus LLC1$22
Apria Healthcare LLC1$22
Astellas Pharma US Inc1$20
Genentech USA, Inc.1$19
Aytu Biopharma, Inc.1$18
Medtronic1$17
Xeris Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,325 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$107,784
Medicare patients
254
Services billed
840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala409$1,844,078
OdefseyEmtricitab/Rilpiviri/Tenof Ala212$879,026
TivicayDolutegravir Sodium251$733,826
DovatoDolutegravir Sodium/Lamivudine173$569,739
DescovyEmtricitabine/Tenofov Alafenam254$564,967
TriumeqAbacavir/Dolutegravir/Lamivudi126$526,355
SerostimSomatropin28$508,524
JulucaDolutegravir/Rilpivirine105$389,374
GenvoyaElviteg/Cob/Emtri/Tenof Alafen82$360,145
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf56$353,043
RukobiaFostemsavir Tromethamine34$306,692
IsentressRaltegravir Potassium136$269,084
Egrifta SvTesamorelin Acetate29$225,902
PifeltroDoravirine94$167,891
CreonLipase/Protease/Amylase49$165,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$41,522$2,769,191745 claims
Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Juluca, Rukobia$13,123$2,615,926701 claims
MerckIsentress, Pifeltro, Delstrigo, Januvia, Janumet$1,357$578,968341 claims
EMD Serono, Inc.Serostim$2,213$508,52428 claims
Janssen Products, LPSymtuza$199$353,04356 claims
Theratechnologies Inc.Egrifta Sv$759$225,90229 claims
AbbVieCreon$2,761$165,18949 claims
Janssen Scientific Affairs, LLCEdurant, Prezista$107$145,41087 claims
Johnson & JohnsonPrezcobix, Xarelto$974$143,85292 claims
Boehringer IngelheimJardiance, Synjardy Xr$318$137,636176 claims
Lilly USA, LLCTrulicity, Mounjaro$1,021$134,377126 claims
Novo NordiskOzempic$1,442$132,465120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →